Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
145
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis143
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC138
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease113
AP&T: Editors' Declarations of Interest106
83
Issue Information72
Issue Information72
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep71
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?69
68
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation67
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy67
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease65
Editorial: The future of managing drug induced liver injury64
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC63
No value of non‐selective beta‐blockers after TIPS‐insertion62
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted62
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply59
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?58
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study58
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply57
Systematic review and meta‐analysis: the incidence and prevalence of paediatric coeliac disease across Europe57
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study55
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply55
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis55
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B53
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply52
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US52
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o50
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough50
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply49
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply48
Editorial: Plants against animals48
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis47
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?47
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?47
Editorial: risk of pneumonia in IBD—reading between the lines!46
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease46
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients45
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease44
Letter: Ozanimod and latent tuberculosis44
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply43
0.062179088592529